2046: Using a Novel Combination of Drugs to Treat Arrhythmia and Heart Failure in Dogs
Grant Status: Open
Atrial fibrillation is a common heart rhythm abnormality (arrhythmia) in dogs. This arrhythmia affects all dog breeds and frequently coexists with heart failure causing worsening of disease and high mortality. Atrial fibrillation may be managed by administering drugs to slow heart rate or by restoring normal rhythm (cardioversion). Dr. Bright will evaluate dogs with naturally occurring atrial fibrillation and heart failure for their responsiveness to two drugs -- amidodarone, an antiarrhythmic agent, and ranolazine, a drug used in humans with coronary heart disease. She will determine whether ranolazine given with amiodarone prolongs normal rhythm compared to amiodarone alone and whether ranolazine also improves heart function. Results will validate combined ranolazine/amiodarone administration as an improved new treatment for atrial fibrillation in dogs with heart failure, extending their quality of life.
None at this time.
Help Future Generations of Dogs
Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.